Literature DB >> 1411334

Where are the women in first-episode studies of schizophrenia?

W G Iacono1, M Beiser.   

Abstract

Almost all investigations of first-episode schizophrenia uncover more male than female subjects. Two possible explanations for this observation are (1) first-episode investigations suffer more or less consistent methodologic biases or (2) the incidence of schizophrenia is higher in men than in women. Data from the markers and predictors of schizophrenia (MAP) project, a community-based first-episode study, permitted an investigation of the two alternatives. The results suggest that neither recruitment nor diagnostic vagaries explain the excess of males. Instead, the MAP results, consistent with other recent investigations, suggest that the incidence of schizophrenia is lower in women than in men. The findings are consistent with the literature on gender differences in schizophrenia, which indicates that schizophrenia in women is a less severe disorder than in men. The report includes recommendations for future first-episode investigations to ensure adequate representation of women.

Entities:  

Mesh:

Year:  1992        PMID: 1411334     DOI: 10.1093/schbul/18.3.471

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  10 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

2.  Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder.

Authors:  Rafael Segarra; Natalia Ojeda; Arantzazu Zabala; Jon García; Ana Catalán; Jose Ignacio Eguíluz; Miguel Gutiérrez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-05-26       Impact factor: 5.270

3.  The hormonal environment in utero as a potential aetiological agent for schizophrenia.

Authors:  Marco Procopio; Russel J E Davies; Paul Marriott
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-29       Impact factor: 5.270

4.  Gender-specific experiences of serious mental illness in rural Ethiopia: A qualitative study.

Authors:  Senait Ghebrehiwet; Tithi Baul; Juliana L Restivo; Teshome Shibre Kelkile; Anne Stevenson; Bizu Gelaye; Abebaw Fekadu; Maji Hailemariam; Eshetu Girma; Solomon Teferra; Victoria Canelos; David C Henderson; Christina P C Borba
Journal:  Glob Public Health       Date:  2019-10-20

5.  The modulation of brain dopamine and GABAA receptors by estradiol: a clue for CNS changes occurring at menopause.

Authors:  R Bossé; T DiPaolo
Journal:  Cell Mol Neurobiol       Date:  1996-04       Impact factor: 5.046

6.  Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis?

Authors:  Michal Arad; Ina Weiner
Journal:  Neuropsychopharmacology       Date:  2010-03-17       Impact factor: 7.853

7.  Predictors of outcome in brief cognitive behavior therapy for schizophrenia.

Authors:  Alison Brabban; Sara Tai; Douglas Turkington
Journal:  Schizophr Bull       Date:  2009-07-01       Impact factor: 9.306

8.  Dopamine and GABAA receptor imbalance after ovariectomy in rats: model of menopause.

Authors:  R Bossé; T Di Paolo
Journal:  J Psychiatry Neurosci       Date:  1995-11       Impact factor: 6.186

Review 9.  Schizophrenia and the life cycle.

Authors:  D A Adler; K Pajer; J M Ellison; R Dorwart; S Siris; H Goldman; A Lehman; J Berlant
Journal:  Community Ment Health J       Date:  1995-06

10.  Multifamily group psychoeducation and cognitive remediation for first-episode psychosis: a randomized controlled trial.

Authors:  Nicholas Jk Breitborde; Francisco A Moreno; Natalie Mai-Dixon; Rachele Peterson; Linda Durst; Beth Bernstein; Seenaiah Byreddy; William R McFarlane
Journal:  BMC Psychiatry       Date:  2011-01-12       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.